Consequently, it is conceivable that MK2 may act as a powerful hallmark of cancer cells and inhibiting MK2 could disrupt tumor growth (7), which provides new avenues to explore the response of cancers to their therapeutic agents. This evidence concerns the gene MAPKAPK2 and cancer.